Scpharmaceuticals Inc 's ROA from the second quarter of 2025 to the second quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Scpharmaceuticals Inc 's ROA in the second quarter of 2025?
Scpharmaceuticals Inc recorded a cumulative net loss of $-92 million during 12 months ending in the second quarter of 2025, resulting in a negative return on assets (ROA) of -92.3%.

However, within the Healthcare sector 759 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2025 quarter, so far to 4409, from total ROA ranking in the first quarter of 2025 at 4489.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter
Y / Y Total Assets Change	25.69 %	16.75 %	13.88 %	18.2 %	-44.83 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-92	-91	-85	-80	-61
Return On Assets (TTM)	-92.3 %	-95.22 %	-92.42 %	-90.11 %	-72.06 %
SCPH's Total Ranking	# 4409	# 4489	# 5166	# 4558	# 4496
Total Assets (TTM) in million	79	89	106	123	63
Seq. Total Assets Change	-11.89 %	-15.58 %	-14.16 %	96.85 %	-18.15 %
Seq. Net Income Change	-	-	-	-	-

SCPH's 5 Years Annual ROA >> Back to SCPH Management Effectiveness >> Compare SCPH ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 353
Sector	# 760
Overall	# 4352

Return On Assets Statistics
High	Average	Low
-8.2 %	-45.64 %	-93.35 %
(Mar 31 2018)		(Mar 31 2025)

Financial Statements
Scpharmaceuticals Inc 's Assets	$ 79 million	SCPH's Balance sheet
Scpharmaceuticals Inc 's Income	$ -18 million	Quarterly SCPH's Income Statement
SCPH's Income by Division		See SCPH's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	13.88 %	-24.62 %	57.46 %	-28.16 %	41.1 %
Total Assets in million	106	93	123	78	109
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-85	-55	-37	-28	-32
Annual Return On Assets	-80.4 %	-58.94 %	-29.86 %	-35.78 %	-29.54 %

SCPH's 5 Years Annual ROA >> Back to SCPH Management Effectiveness >> Compare SCPH ROA to its Competitors

More Return On Assets Ratios
SCPH's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SCPH's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SCPH's Competitors
Subscribers only: Roa for Scpharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for SCPH's Customers

You may also want to know
SCPH's Roi	SCPH's Inventory Turnover Ratio	SCPH's Growth Rates	SCPH's Dividend Comparisons
	SCPH's Profitability Ratios	SCPH's Asset Turnover Ratio	SCPH's Dividend Growth
SCPH's Roe	SCPH's Valuation Ratios	SCPH's Financial Strength Ratios	SCPH's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2025, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:11:32+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.